BostonGene touts prostate cancer research results

2021 01 16 00 14 5464 Prostate Cancer 400

Biomedical software firm BostonGene is highlighting research published in Clinical Cancer Research that identified particular molecular, cellular, and structural characteristics associated with MRI-visible, clinically significant prostate cancer.

The research was conducted by a team of oncologists at Washington University School of Medicine in St. Louis in partnership with the company. The investigators conducted a multiomics analysis of multiparametric MRI (mpMRI)-invisible and visible prostate cancer using BostonGene's artificial intelligence (AI)-based immunofluorescence single-cell spatial imaging and gene expression profiling.

In addition to identifying characteristics of MRI-visible, clinically significant prostate cancer, the researchers also found that tumors invisible on mpMRI were similar to normal prostate tissue. What's more, the expression profiling identified a stromal enrichment signature in mpMRI-invisible prostate cancers that correlated with better clinical outcomes, according to the researchers.

"This AI-based analytical approach could distinctly identify the molecular and cellular composition of tumor tissue," said study lead author Dr. Russell Pachynski in a statement released by BostonGene. "Integrated multiomics analysis in conjunction with mpMRI shows promise for the diagnosis and personalization of treatment options for patients with clinically significant prostate cancer."

Page 1 of 609
Next Page